News | October 16, 2007

Sirolimus Stents Exacerbate Endothelial Injury after MI

October 17, 2007 - Compared to bare metal stents, in patients with acute myocardial infarction, sirolimus-eluting stent (SES) implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery, Japanese researchers report in the October 2nd issue of the Journal of the American College of Cardiology.

Kiyotaka Kugiyama, M.D., and colleagues at the University of Yamanashi, Chuo City note that drug-eluting stents reduce restenosis rates and revascularization but may impair recovery from reperfusion-induced endothelial injury.

To investigate, the researchers studied 29 patients with a first acute MI of the left anterior descending coronary artery (LAD). Thirteen had successful reperfusion therapy using an SES and the remaining 16 also had successful therapy employing a bare metal stent.

At two weeks, following intracoronary infusion of acetylcholine, the epicardial coronary artery became more severely restricted in the SES than the bare metal group. SES patients also had a lower increase in coronary blood flow in response to the agent.

In addition, levels of vascular endothelial growth factor (VEGF) in the anterior interventricular vein were significantly lower than in the aortic root in SES patients. This was not the case in the bare metal group.

The researchers stress that larger randomized studies are needed to confirm these findings. However, "these findings suggest that SES implantation may decrease the release of VEGF from the myocardial region supplied by the LAD, which may play a possible role in endothelial vasomotor dysfunction in infarct-related coronary arteries treated with SES."

Reference: J Am Coll Cardiol 2007;50:1305-1309

Source: Reuters

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init